Mathematical modeling of the effects of glutathione on arsenic methylation

Theoretical Biology and Medical Modelling

Volumn 11, Issue 1, 2014, Pages

  Lawley, Sean D ^a   Yun, Jina ^a   Gamble, Mary V ^b   Hall, Megan N ^b   Reed, Michael C ^a   Nijhout, H Frederik ^a  

^a DUKE UNIVERSITY   (United States)

^b Mailman School of Public Health   (United States)

Author keywords

Arsenic; Detoxification; Glutathione; Mathematical model; Methylation

Indexed keywords

ARSENIC; GLUTATHIONE;

ANIMAL; ARTICLE; DRUG DETOXIFICATION; METABOLISM; METHYLATION; RAT; STATISTICAL MODEL; URINE;

ANIMALS; ARSENIC; GLUTATHIONE; METABOLIC DETOXICATION, DRUG; METHYLATION; MODELS, STATISTICAL; RATS;

EID: 84901946102     PISSN: None     EISSN: 17424682     Source Type: Journal    
DOI: 10.1186/1742-4682-11-20     Document Type: Article

References (59)

1. Ensuring safe drinking water in Bangladesh. Ahmed MF, Ahuja S, Alauddin M, Hug SJ, Lloyd JR, Pfaff A, Pichler T, Saitikov C, Stute M, vanGeen A, Science 2006 314 1687 1688 10.1126/science.1133146 17170279 (Pubitemid 44969061)
2. Arsenic contamination of groundwater in Bangladesh. Final report. Kinniburgh DG, Smedley PL, Tech. Rep. WC/00/19, British Geological Survey, Keyworth, UK, 2001
3. Arsenic, organic foods, and brown rice syrup. Jackson BP, Karagas VFTMR, Punshon T, Cottingham KL, Environ Health Perspect 2012 120 623 626 10.1289/ehp.1104619 22336149
4. Water arsenic exposure and children's intellectual function in Araihazar, Bangladesh. Wasserman GA, Liu X, Parvez F, Ahsan H, Factor-Litvak P, vanGeen A, Slavkovic V, Lolacano NJ, Cheng Z, Iftikhar H, Momotaj H, Graziono JH, Environ Health Perspect 2004 112 1329 1333 10.1289/ehp.6964 15345348 (Pubitemid 39294973)
5. Water arsenic exposure and intellectual function in 6-year-old children in Araihazar, Bangladesh. Wasserman GA, Liu X, Parvez F, Ahsan H, Factor-Litvak P, Kline J, vanGeen A, Slavkovic V, Lolacano NJ, Levy D, Cheng Z, Graziono JH, Environ Health Perspect 2007 115 285 289 17384779
6. Biological methylation. Challenger F, Adv Enzymol Biochem 1951 12 429 491
7. Comparative methylation of trivalent and pentavalent arsenicals. Styblo M, Yamauchi H, Thomas DJ, Toxicol Appl Pharmacol 1995 135 172 178 10.1006/taap.1995.1220 8545824 (Pubitemid 26031867)
8. Methylation of inorganic arsenic in different mammalian species and population groups. Vahter M, Sci Prog 1999 82 69 88 10445007
9. Monomethylarsonous acid (MMA(III)) is more toxic than arsenite in Chang human hepatocytes. Petrick JS, Ayala-Fierro F, Cullen WR, Carter DE, Aposhian HV, Toxicol Appl Pharmacol 2000 163 203 207 10.1006/taap.1999.8872 10698679 (Pubitemid 30152096)
10. Comparative toxicity of trivalent and pentavalent inorganic and methylated arsenicals in rat and human cells. Styblo M, DelRazo LM, Vega L, Germolec DR, LeCluyse EL, Hamilton GA, Reed W, Wang C, Cullen WR, Thomas DJ, Arch Toxicol 2000 74 289 299 10.1007/s002040000134 11005674 (Pubitemid 30660931)
11. Possible role of dimethylarsinous acid in dimethylarsinic acid-induceD urothelial toxicity and regeneration in the rat. Cohen SM, Arnold LL, Uzvolgyi E, Cano M, John MS, Yamamoto S, Lu X, Li XC, Chem Res Toxicol 2002 15 1150 1157 10.1021/tx020026z 12230408
12. The reaction of methylarsenicals with thiols: some biological implications. Cullen WR, McBride BC, Reglinski J, J Inorganic Chem 1984 21 179 194
13. Reduction and binding of arsenate and dimethylarsinate by glutathione: a magnetic resonance study. Delnomdedieu M, Basti MM, Otvos JD, Thomas DJ, Chemico-Biological Inter 1994 90 139 155 10.1016/0009-2797(94)90099-X (Pubitemid 24103849)
14. Complexation of arsenic species in rabbit erythrocytes. Delnomdedieu M, Basti MM, Styblo M, Otvos JD, Thomas DJ, Chem Res Toxicol 1994 7 621 627 10.1021/tx00041a006 7841340 (Pubitemid 24302157)
15. Monomethylarsonic acid reductase and monomethylarsonous acid in hamster tissue. Sampayo-Reyes A, Zakharyan RA, Healy SM, Aposhian HV, Chem Res Toxicol 2000 13 1181 1186 10.1021/tx000154s 11087441
16. V ) reductase is a member of the glutathione S-transferase superfamily. Zakharyan RA, Sampayo-Reyes A, Healy SM, Tsaprailis G, Board PG, Liebler DC, Aposhian HV, Chem Res Toxicol 2001 14 1051 1057 10.1021/tx010052h 11511179 (Pubitemid 32800161)
17. Endogenous reductants support the catalytic function of recombinant rat cyt19, an arsenic methyltransferase. Waters SB, Devesa V, Razo LMD, Styblo M, Thomas DJ, Chem Res Toxicol 2004 17 404 409 10.1021/tx0342161 15025511 (Pubitemid 38375065)
18. Glutathione modulates recombinant rat arsenic (+3 oxidation state) methyltransferase-catalyzed formation of trimethylarsine oxide and trimethylarsine. Waters SB, Devesa V, Fricke MW, Creed JT, Styblo M, Thomas DJ, Chem Res Toxicol 2004 17 1621 1629 10.1021/tx0497853 15606138 (Pubitemid 39665554)
19. Methylation of arsenic by recombinant human wild-type arsenic (+3 oxidation state) methyltransferase and its methionine 287 threonine (M287T) polymorph: Role of glutathione. Ding L, Saunders RJ, Drobna Z, Walton FS, Xun P, Thomas DJ, Styblo M, Toxicol Appl Pharmacol 2012 264 121 130 10.1016/j.taap.2012.07.024 22868225
20. New insights into the mechanism of arsenite methylation with the recombinant human arsenic (3) methyltransferase (hAS3MT). Song X, Geng Z, Li X, Hu X, Bian N, Zhang X, Wang Z, Biochimie 2010 92 1397 1406 10.1016/j.biochi. 2010.07.002 20621156
21. A new metabolic pathway of arsenite: arsenic-glutathione complexes are substrates for human arsenic methyltransferase Cyt19. Hayakawa T, Kobayashi Y, Cui X, Hirano S, Arch Toxicol 2005 79 4 183 191 10.1007/s00204-004-0620-x 15526190 (Pubitemid 40603183)
22. Chemical mechanism of arsenic biomethylation. Cullen WR, Chem Res Toxicol 2014 27 4 457 461 10.1021/tx400441h 24517124
23. Identification of Catalytic Residues in the As(III)S-Adenosylmethionine Methyltransferase. Marakapala K, Qin J, Rosen BP, Biochemistry 2012 51 944 951 10.1021/bi201500c 22257120
24. Rapid equilibrium kinetic analysis of arsenite methylation catalyzed by recombinant human arsenic (+3 oxidation state) methyltransferase (hAS3MT). Wang S, Li X, Song X, Geng Z, Hin X, Wang Z, J Biol Chem 2012 287 38790 38799 10.1074/jbc.M112.368050 22955273
25. The MRP2/cMOAT transporter and arsenic-glutathione complex formation are required for biliary excretion of arsenic. Kala SV, Neely MW, Kala G, Prater CI, Atwood DW, Rice JS, Liebermann MW, J Biol Chem 2000 275 33404 33408 10.1074/jbc.M007030200 10938093
26. Comparison of the urinary excretion of arsenic metabolites after a single oral dose of sodium arsenite, monomethylarsonate, or dimethylarsinate in man. Buchet JP, Lauwerys R, Roels H, Occup Environ Health 1981 48 71 79 10.1007/BF00405933 (Pubitemid 11130215)
27. Urinary excretion of inorganic arsenic and its metabolites after repeated ingestion of sodium metaarsenite by volunteers. Buchet JP, Lauwerys R, Roels H, Occup Environ Health 1981 48 111 118 10.1007/BF00378431 (Pubitemid 11121113)
28. Folate and arsenic metabolism: a double-blind, placebo-controlled folic acid-supplementation trial in Bangladesh. Gamble MV, Liu X, Ahsan H, Pilsner JR, Ilievski V, Slavkovich V, Parvez F, Chen Y, Levy D, Factor-Litvak P, Graziano JH, Am J Clin Nutr 2006 84 1093 1101 17093162 (Pubitemid 44730380)
29. Folic acid supplementation lowers blood arsenic. Gamble MV, Liu X, Slavkovich V, Pilsner JR, Ilievski V, Factor-Litvak P, Levy D, Alam S, Islam M, Parvez F, Ahsan H, Graziano JH, TAm J Clin Nutr 2007 86 1202 09 (Pubitemid 47538328)
30. Mathematical model insights into arsenic detoxicfication. Lawley SD, Cinderella M, Hall MH, Gamble MV, Nijhout HF, Reed MC, Theor Biol Med Model 2011 8 1 17 10.1186/1742-4682-8-1 21247471
31. A physiologically based pharmacokinetic model for arsenic exposure I. Development in hamsters and rabbits. Mann S, Droz PO, Vahter M, Toxicol Appl Pharamacol 1996 137 8 22 10.1006/taap.1996.0052 (Pubitemid 26095854)
32. A physiologically based pharmacokinetic model for arsenic exposure II. Humans. Mann S, Droz PO, Vahter M, Toxicol Appl Pharamacol 1996 140 471 486 10.1006/taap.1996.0244 (Pubitemid 26366872)
33. Physiologically based pharmocokinetic modeling of arsenic in the mouse. Gentry PR, Covington TR, Mann S, Shipp AM, Yager JW, Clewell HJ III, J Toxicol Environ Health 2004 67 43 71 10.1080/15287390490253660 (Pubitemid 38117531)
34. A physiologically based pharmacokinetic model of inorganic arsenic. Yu D, Regul Toxicol Pharmacol 1999 29 128 141 10.1006/rtph.1999.1282 10341143 (Pubitemid 29262044)
35. Development of a human physiologically based pharmacokinetic (PBPK) model for inorganic arsenic and its mono- and di-methylated metabolites. El-Masri HA, Kenyon EM, J Pharmacokinet Pharmacodyn 2008 35 31 68 10.1007/s10928-007-9075-z 17943421 (Pubitemid 351420762)
36. Metabolism of arsenic in primary cultures of human and rat hepatocytes. Styblo M, Razo LMD, LeCluyse EL, Hamilton GA, Wang C, Cullen WR, Thomas DJ, Chem Res Toxicol 1999 12 560 565 10.1021/tx990050l 10409394 (Pubitemid 29354737)
37. Application of modeling techniques to planning of in vitro arsenic pharmacokinetic studies. Kenyon EM, Fea M, Styblo M, Evans MV, Alter Lab Animals 2001 29 15 33 (Pubitemid 32157261)
38. Pharmacokinetic modeling of arsenite uptake and metabolism in hepatocytes- mechanistic insights and implications for further experiments. Easterling MR, Styblo M, Evans MV, Kenyon EM, J Pharmacokin Pharmacodyn 2002 29 3 207 234 10.1023/A:1020248922689 (Pubitemid 35333140)
39. Mathematical model of uptake and metabolism of arsenic(III) in human hepatocytes-Incorporation of cellular antioxidant response and thresholddependent behavior. Stamatelos SK, Brinkerhof CJ, Georgeopoulos SSIPG, BMC Syst Biol 2011 5 1 15 10.1186/1752-0509-5-1 21194489
40. A semi-mechanistic integrated toxicokinetic-toxicodynamic (TK/TD) model for arsenic(III) in hepatocytes. Stamatelos SK, Androulakis IP, Kong AT, Georopoulos PG, J Theor Biol 2013 317 244 256 23069314
41. Human arsenic methyltransferase (AS3MT) pharmacogenetics. Wood TC, Salavigionne OE, Mukherjee B, Wang L, Klumpp AF, Thomae BA, Eckloff BW, Schaid DJ, Wieben ED, Weinshilboum RM, J Biol Chem 2006 281 11 7364 7373 10.1074/jbc.M512227200 16407288 (Pubitemid 43847506)
42. Kinetics of arsenic methylation by freshly isolated B6C3F1 hepatocytes. Kedderis GL, Elmore AR, Crecelius EA, Yager JW, Goldsworthy TL, Chem-Biol Interact 2006 161 139 145 10.1016/j.cbi.2006.04.001 (Pubitemid 43776627)
43. Enzymatic methylation of arsenic compunds. VII. Monomethylaraonous acid (MMAIII) Is the substrate for MMA Methyltransferase of rabbit liver and human hepatocytes. Zakharyan RA, Ayala-Fierro F, Cullen WR, Carter DM, Aposhian HV, Toxicol Appl Pharmacol 1999 158 9 15 10.1006/taap.1999.8687 10387927 (Pubitemid 29316221)
44. Role of thiols in the in vitro methylation of inorganic arsenic. Buchet JP, Lauwerys R, Biochem Pharmacol 1988 37 3149 3153 10.1016/0006-2952(88)90313-9 3401245
45. Reactions of arsenic(III) and arsenic(V) species with glutathione. Scott N, Hatlelid KM, MacKenzie NE, Carter DE, Chem Res Toxicol 1993 6 102 106 10.1021/tx00031a016 8448339 (Pubitemid 23040380)
46. Glutathione transport across hepatocyte plasma membranes. Inoue M, Kinne R, Trans T, Arias I, Eur J Biochem 1984 138 491 495 10.1111/j.1432-1033.1984. tb07943.x 6692832
47. Glutathione metabolism and its implications for health. Wu G, Fang Y, Lupton JR, Turner ND, J Nutr 2004 134 489 492 14988435 (Pubitemid 38298485)
48. Glutathione degradation is a key determinant of glutathione homeostasis. Baudouin-Cornu P, Lagniel G, Kumar C, Huang ME, Labarre J, J Biol Chem 2012 287 4552 4561 10.1074/jbc.M111.315705 22170048
49. The stabilities of various thiol compounds used in protein purifications. Stevens R, Stevens L, Price NC, Biochem Ed 1983 11 2 70 10.1016/0307-4412(83) 90048-1
50. A mathematical model gives insights into nutritional and genetic aspects of folate-mediated one-carbon metabolism. Reed M, Nijhout HF, Neuhouser M, Shane B, James SJ, Boynton A, Ulrich CM, III JFG, J Nutr 2006 136 2653 2661 16988141 (Pubitemid 44521628)
51. Glutathione-dependent biliary excretion of arsenic. Gyurasics A, Varga F, Gregus Z, Biochem Pharmacol 1991 42 465 468 10.1016/0006-2952(91)90306-P 1859460
52. A mathematical model of glutathione metabolism. Reed MC, Thomas RL, Pavisic J, James SJ, Ulrich CM, Nijhout HF, Theor Biol Med Model 2008 5 8 10.1186/1742-4682-5-8 18442411 (Pubitemid 351728047)
53. Guidelines for the management of paracetamol poinsoning in Australia and New Zealand-explanation and elaboration. Daly FF, Fountain JS, Murray L, Graudins A, Buckley NA, Med J Australia 2008 188 296 301 18312195
54. The biochemistry of acetaminophen hepatotoxicity and rescue. Ben-shachar R, Chen Y, Luo S, Hartman C, Reed M, Nijhout HF, Theor Biol Med Model 2012 9 55 10.1186/1742-4682-9-55 23249634
55. The effect of glutamine supplementation in patients following elective surgery and accidental injury. Wilmore D, J Nutr 2001 131 2543S 2549S 11533310 (Pubitemid 32847007)
56. Regulative potential of glutathione-relation to glutathione metabolism. Roth E, Oehler R, Manhart N, Exner R, Wessner B, Strasser E, Spittler A, Nutrition 2002 18 217 221 10.1016/S0899-9007(01)00797-3 11882392 (Pubitemid 34204130)
57. Chronic arsenic exposure and blood glutathione and glutathione disulfide concentrations in Bangladeshi adults. Hall MN, Niedzwiecki M, Liu X, Harper KN, Alam S, Slavowich V, Ilievski V, Levy D, Siddique AB, Parvez F, Mey JL, Geen AV, Graziano J, Gamble MV, Environ Health Per 2013 121 1068 1074
58. Homocysteine metabolism in children with down syndrome: In Vitro modulation. Pogribna M, Melnyk S, Pogribny I, Chango A, Yi P, James SJ, Am J Hum Genet 2001 69 88 95 10.1086/321262 11391481 (Pubitemid 32614021)
59. Metabolic biomarkers of increased oxidative stress and impaired methylation capacity in children with autism. James SJ, Cutler P, Melnyk S, Jernigan S, Janak L, Gaylor DW, Neubrander JA, Am J Clin Nutr 2004 80 1611 1617 15585776 (Pubitemid 41103861)